Mitogen-activated protein kinase pathways and cardiac surgery  by Khan, Tanveer A. et al.
Mitogen-activated protein kinase pathways and cardiac
surgery
Tanveer A. Khan, MD
Cesario Bianchi, MD, PhD
Marc Ruel, MD, MPH
Pierre Voisine, MD
Frank W. Sellke, MD
A list of 74 references is avail-
able online.
Mitogen-activated protein kinases are serine-threonine protein kinases that are
involved in several processes important to cardiac surgery such as vascular
permeability, cytokine production, vasomotor function, and reperfusion injury. Mi-
togen-activated protein kinases are expressed in multiple cell types including
cardiomyocytes, vascular endothelial cells, and vascular smooth muscle cells.
Mitogen-activated protein kinases function in cellular signal transduction cascades
and are activated by a diverse range of stimuli including ischemia, shear stress, and
vasoactive agents. Three major mitogen-activated protein kinase families were
identified as the extracellular signal-regulated kinases, c-Jun NH2-terminal protein
kinases, and p38 kinases. Extensive investigation has established roles for extra-
cellular signal-regulated kinases, c-Jun NH2-terminal protein kinases, and p38
kinases in cardiovascular signal transduction pathways. Activity of these signal
cascades may contribute to the increased pulmonary vascular permeability and
myocardial reperfusion injury observed after cardiac surgery with cardioplegia and
cardiopulmonary bypass. Recent findings from our laboratory suggest that alter-
ations in the activity of myocardial extracellular signal-regulated kinase pathways
occur as a result of cardioplegia– cardiopulmonary bypass in humans. In addition,
these differences in extracellular signal-regulated kinase activity were shown to
mediate coronary microcirculatory dysfunction associated with cardioplegia– car-
diopulmonary bypass. The resulting deficit in coronary microcirculatory regulation
may potentially lead to detrimental effects on organ perfusion and function. As
mitogen-activated protein kinase pathways are further characterized, our potential
to develop methods to prevent morbidity associated with cardiac surgery and
cardiopulmonary bypass may be greatly improved.
Mitogen-activated protein kinases (MAPK) are serine-threonineprotein kinases that are involved in several processes impor-tant to cardiac surgery such as vascular permeability, cytokineproduction, vasomotor function, and reperfusion injury.MAPK are expressed in multiple cell types including cardi-omyocytes, vascular endothelial cells, and vascular smooth
muscle cells. MAPK function in cellular signal transduction cascades and are
activated by a diverse range of stimuli including ischemia, shear stress, and
vasoactive agents. The basic structure of the pathway consists of a sequential,
3-kinase module: a MAPK kinase kinase (MAPKKK) that phosphorylates and
activates a MAPK kinase (MAPKK), which in turn activates a MAPK. Three major
MAPK families were identified as the extracellular signal-regulated kinases (ERK),
c-Jun NH2-terminal protein kinases (JNK), and p38 kinases. Extensive investigation
has established roles for ERK, JNK, and p38 kinase in the regulation of cardiovas-
cular signal transduction pathways. Recent findings from our laboratory suggest that
the ERK pathway mediates coronary microcirculatory dysfunction associated with
cardioplegia and cardiopulmonary bypass (CPB) in humans. In this review, the
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characteristics of MAPK signaling pathways will be pre-
sented as well as evidence to support MAPK cascades in the
regulation of vascular endothelial cell permeability, produc-
tion of cytokines, modulation of vasomotor function, and
mediation of reperfusion injury. In addition, the potential
roles of these protein kinases in microcirculatory dysfunc-
tion due to cardioplegia and CPB shall be discussed.
MAPK Signal Transduction Cascades
The three-kinase regulatory module of the MAPK pathways
was defined with the identification of the protein kinases
upstream of ERK.1 MAPK are activated by phosphorylation
to create an active, dual-phosphorylated form. The module
is a regulatory scheme of sequential protein kinase phos-
phorylation and activation. MAPK then function to phos-
phorylate serine and threonine residues of their substrates,
many of which are transcription factors, which are accessed
after MAPK translocation across the nuclear membrane.2
Protein kinase phosphatases such as MAPK phosphatase-1
(MKP-1) also regulate MAPK activity by dephosphoryla-
tion, resulting in the deactivation of MAPK. MKP-1 expres-
sion is induced by factors such as oxidative stress that also
activate the MAPK, thus suggesting a negative feedback
loop.3
ERK Pathway
The original MAPK was described as a 42-kDa serine-
threonine protein kinase activated by several extracellular
stimuli.4 The MAPK was named extracellular signal-regu-
lated kinase (ERK) based on the multiplicity of extracellular
signals capable of activating the kinase.5 Notable among the
variety of extracellular stimuli are growth factors, shear
stress, and cytokines.6-8 Among the several forms of ERK,
the 42-kDa (ERK1) and 44-kDa (ERK2) forms are the most
widely studied. The ERK three-kinase module is the best
described of the MAPK signaling pathways (Figure 1). The
Raf kinases function as MAPKKK of the ERK pathway.
MAPK/ERK kinase 1/2 (MEK1/2) follows as the down-
stream MAPKK,9 which activates ERK by phosphorylation
of the activation loop of the catalytic domain.10 ERK phos-
phorylates substrates in both cytoplasmic and nuclear cel-
lular compartments. Among proteins phosphorylated in the
cytosol are ribosomal S6 kinase p90 and cytosolic phospho-
lipase A2.11,12 Cytosolic phospholipase A2 is involved in the
production of arachidonic acid, the rate-limiting step in the
synthesis of prostaglandins and leukotrienes.12 Activated
ERK is translocated to the nucleus and capable of phos-
phorylating multiple different transcription factors includ-
ing Elk-1.2
Figure 1. MAPK activation, regulation, and downstream effects. The ERK three-kinase regulatory module is shown
as a representative MAPK pathway. Multiple extracellular signals activate the ERK1/2 cascade including oxidative
stress, vasoactive agents, cytokines, shear stress, and growth factors. Raf, an MAPK kinase kinase, and MEK1/2,
an MAPK kinase, transmit signals to ERK1/2, which is activated by dual phosphorylation. Activated ERK1/2 is
involved in several physiologic processes of cardiovascular significance such as vascular permeability, cytokine
production, vasomotor function, and reperfusion injury. ERK1/2 is dephosphorylated and deactivated by MKP-1.
ERK1/2, extracellular signal-regulated kinase 1/2; MAPK, mitogen-activated protein kinase; MEK1/2, MAPK/ERK
kinase 1/2; MKP-1, MAPK phosphatase-1.
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JNK Pathway
JNK was identified as a MAPK distinguishable from ERK
by phosphorylating the transcription factor c-Jun at the
NH2-terminal transactivation domain instead of the COOH-
terminal site where it is phosphorylated by ERK.13 The JNK
cascade is activated by several forms of cell stress such as
heat shock, radiation, and oxidation, as well as the binding
of ligands to extracellular receptors including G protein–
coupled, tyrosine kinase, and cytokine receptors.14 Note-
worthy among cytokines that activate JNK are the inflam-
matory mediators tumor necrosis factor (TNF)- and
interleukin (IL)-1. In addition to c-Jun, JNK phosphorylates
transcription factors such as p5315 and Elk-1,2 which is a
point of convergence of the ERK, JNK, and p38 pathways.
p38 Kinase Pathway
p38 kinase was identified as a 38-kDa protein kinase with
49% sequence homology to ERK.16 p38 kinases also are
activated by cellular stress and certain cytokines, notably
IL-1 and TNF-.17-19 Accordingly, JNK and p38 kinase are
known as stress-activated protein kinases. Similar to ERK
and JNK, p38 activation is accomplished by dual phosphor-
ylation of threonine and tyrosine residues.17 p38 phosphor-
ylates transcription factors such as Elk-120 and myocyte
enhancer factor 2.21
Activation of MAPK in Cardiovascular Tissue
Cellular Stress
During cardiac surgery, myocardial tissue is exposed to
stresses that are capable of activating MAPK cascades such
as shear stress, stretch, and ischemia. In cultured cardiac
myocytes, shear stress and mechanical stretch activate
MAPK.22 Pulsatile stretch also was demonstrated to induce
phosphorylation of ERK, JNK, and p38 kinase.23 Oxidative
stress was shown to activate MAPK, as demonstrated by
hydrogen peroxide activating MAPK in both cultured car-
diac myocytes24,25 and perfused heart models.26 Thus, the
production of reactive oxygen and nitrogen intermediates
during CPB and reperfusion may alter MAPK activity and
potentially contribute to processes such as reperfusion in-
jury.27,28
Vasoactive Agents and G Protein–Coupled Receptors
MAPK pathways are stimulated by several vasoactive
agents, many of which transmit signals by way of G pro-
tein–coupled receptors.29 Phenylephrine, endothelin-1, and
angiotensin II were shown to activate MAPK. In a perfused
rat heart model, ERK, JNK, and p38 kinase were shown to
be activated by phenylephrine.30 Treatment of cardiac myo-
cytes with endothelin-1 activates ERK1/2, JNK, and
p38.31,32 Angiotensin II increases ERK activity in rat cor-
onary microvascular endothelial cells and both ERK and
JNK activity in rat ventricular myocytes.33 In an in vivo
animal model, intravenous infusion of angiotensin II acti-
vated JNK and to a lesser extent ERK.34 These mechanisms
of activation are significant in light of the frequency with
which phenylephrine, angiotensin-converting enzyme
(ACE) inhibitors, and angiotensin II receptor antagonists
are used in patients having cardiac surgery. The use of these
agents may modify MAPK pathway activity and result in
alterations in downstream cellular events that regulate such
functions as vascular permeability, cytokine production, and
vasomotor tone.
Several lines of evidence suggest MAPK activation via
G protein–coupled receptors is instrumental in the devel-
opment of cardiac hypertrophy.29,35 However, in a study of
cardiac MAPK in humans, no activation was seen in pa-
tients with cardiac hypertrophy.36 Further investigation will
determine a more complete picture of the role of MAPK
pathways in the regulation of the cardiac hypertrophic re-
sponse.
MAPK in Cardiovascular Physiology
Vascular Permeability
MAPK pathways have been implicated in the development
of vascular endothelial permeability, which may become
clinically manifest as organ edema and dysfunction.
ERK1/2 and p38 kinase were shown to regulate permeabil-
ity of endothelial cells,37 and an in vivo model demonstrated
reduced peripheral edema in animals treated with a MEK
inhibitor.38 Studies using bovine pulmonary artery endothe-
lial cells have demonstrated that regulation of permeability
is a function of MAPK pathway activation.39 In the isolated,
blood-perfused rat lung, ERK1/2 activation was associated
with alterations of the capillary barrier.40 Finally, p38 was
shown to increase endothelial cell layer permeability
through alterations in vascular endothelial (VE)-cadherins,
components of cellular adherens junctions.41 A study from
our laboratory demonstrated degradation of VE-cadherins
during CPB, providing a potential mechanism of increased
vascular permeability.42 Thus, MAPK cascades may be
involved in mechanisms causing increased vascular perme-
ability during and after CPB, leading to organ edema with
potential detrimental outcomes such as myocardial dysfunc-
tion and pulmonary insufficiency.
Cytokine Production
The generation of inflammatory cytokines has been shown
to involve MAPK pathways. In an isolated, perfused rat
heart model, inhibition of p38 kinase resulted in diminished
myocardial TNF- production after oxidant stress.43 p38
kinase also was suggested to play a prominent role in the
regulation of IL-1 production by macrophages.44 In cardiac
myocytes, MAPK were shown to regulate IL-6 gene expres-
sion.45 In cardiac fibroblasts, IL-6 gene expression induced
by angiotensin II was shown to be mediated by ERK and
p38 kinase.46 A study of human pulmonary vascular endo-
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thelial cells revealed that IL-8 production induced by expo-
sure to TNF- and IL-1 is dependent on p38 kinase.47 These
findings illustrate that in multiple cell types, MAPK mediate
cytokine production, which is a prominent feature of the
inflammatory response to CPB.
Vasomotor Function
The ubiquitous nature of MAPK is well illustrated by their
role in vasomotor regulation in the cerebral, coronary, pul-
monary, gastrointestinal, and renal circulations. MAPK
pathways were implicated in cerebral artery contraction
induced by low extracellular magnesium concentration.48
Similarly, coronary smooth muscle contraction by endothe-
lin-1 was shown to involve a MAPK-dependent mecha-
nism.49 p38 kinase and hsp27 were shown to mediate pul-
monary vascular smooth muscle contraction.50 In
mesenteric vessels, inhibition of the ERK and p38 kinase
pathways reduces the contractile response to norepineph-
rine.51 Finally, blockade of MAPK activation attenuates
renal artery contraction in response to serotonin receptor
stimulation.52
Reperfusion Injury
Reperfusion injury constitutes a significant pathophysio-
logic mechanism in cardiac surgery that contributes to post-
operative myocardial dysfunction. ERK, JNK, and p38 ki-
nase were shown to be activated in animal models of
myocardial reperfusion injury.53,54 In an isolated, perfused
heart model of reperfusion injury, ERK1/2 activity was
observed to improve cardiac functional recovery, where as
p38 kinase activity was related to myocardial dysfunction.55
Additional support for a cytoprotective effect of ERK1/2
was shown in a study using the cytokine cardiotrophin-1.
Treatment of cultured cardiac myocytes with cardiotro-
phin-1 reduced apoptosis after ischemia and reperfusion by
an ERK1/2-dependent mechanism.56 Consistent with the
proposed role of p38 in apoptosis,57 evidence suggests the
alpha isoform contributes to reperfusion injury.58 Further-
more, p38 inhibition exerts a protective effect from reper-
fusion injury by prevention of upregulation of adhesion
molecules P-selectin and intercellular adhesion molecule-1
and polymorphonuclear leukocyte tissue infiltration.59 Fi-
nally, cardiac arrhythmias are well-described manifestations
of reperfusion injury, and MAPK were suggested to be
involved in the molecular mechanism of atrial fibrilla-
tion.60,61 Further investigation of the MAPK pathways will
lead to a better understanding of the possible protective role
of ERK1/2 and proposed detrimental effect of p38 kinase in
reperfusion injury that contributes to myocardial dysfunc-
tion, seen clinically as postoperative low cardiac output
syndrome.
Studies of myocardial ischemia and reperfusion have
suggested a role for apoptosis in reperfusion injury.62 Ap-
optosis is a specific form of cell death distinct from necrosis
and marked by a specific morphology and relative lack of
inflammation.63 ERK was demonstrated to provide a cyto-
protective effect and prevent apoptosis.55,64 Despite evi-
dence to support JNK and p38 mechanisms in cardiomyo-
cyte apoptosis65,66 other reports document JNK and p38
activity promoting cell survival.67,68 Whether JNK and p38
mediate apoptosis or promote cell survival may be influ-
enced by factors such as the particular isoform activated, as
seen with p38 and p3857 and JNK1 and JNK2,69 or the
duration of MAPK activation.70
Response of MAPK to Cardioplegia and CPB
Evidence from recent studies suggests that cardioplegia and
CPB cause alterations in the activity of MAPK pathways,
potentially resulting in pathophysiologic responses such as
coronary microvascular dysfunction. The activity of MAPK
pathways in response to CPB was characterized in tissue
from animal models. In a study from our laboratory using a
pig model of CPB, elements of the ERK pathway including
activated MEK1/2 and activated ERK1/2 were shown to be
decreased following CPB in atrial and ventricular myocar-
dial tissue. The activated forms of ERK1/2 were decreased
post-CPB, but the total protein levels of ERK1/2 were
unchanged. Although levels of activated MEK1/2 and
ERK1/2 decreased, MKP-1 levels increased post-CPB.
MKP-1, which may be activated by oxidative stress during
reperfusion, potentially dephosphorylates and deactivates
ERK1/2 post-CPB.71 Further investigation of the response
of the ERK1/2 pathway to CPB in our pig model revealed
that activation of ERK1/2 occurred during CPB, which was
then followed by the previously observed deactivation of
ERK1/2 during post-CPB reperfusion. Thus, the activity of
myocardial ERK1/2 pathways in response to CPB in our
animal model is characterized by oscillations seen as acti-
vation during CPB and deactivation to below baseline levels
during post-CPB reperfusion. Oscillations in ERK1/2 and
MEK1/2 activity were also observed in skeletal muscle and
mesenteric vessels, suggesting systemic changes in MAPK
activity with potential effects on vascular permeability, cy-
tokine production, and vasomotor function, as well as a
contributing role in reperfusion injury.72
Recently, we observed that activated ERK1/2 similarly
was decreased in atrial myocardial tissue following cardio-
plegia and CPB in patients during cardiac surgery (Figure
2). Consistent with our animal model, MKP-1 levels also
were increased post-CPB. In addition, the basal vasomotor
tone of coronary arterioles from these patients was signifi-
cantly reduced post-CPB. Treatment of the human coronary
microvessels with a MEK1/2 inhibitor, PD98059, caused a
similar loss of basal tone (unpublished data). These findings
provided evidence to suggest that decreased ERK1/2 activ-
ity post-CPB in part mediates coronary microvascular dys-
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function in patients who undergo cardiac surgery. Dysfunc-
tion of the coronary microcirculation due to CPB may result
in detrimental changes in myocardial perfusion and func-
tion.73 A previous report of MAPK activity in atrial myo-
cardial tissue from patients undergoing cardiac surgery de-
scribed increased levels of activated ERK1/2, JNK, and p38
following cardioplegia and CPB.74 The difference may rep-
resent a pattern of oscillation between activation and deac-
tivation of MAPK pathways during CPB and reperfusion,
which was suggested in the study from our laboratory.72
Overall, these studies illustrate that alterations in MAPK
cascades are significant during cardiac surgery and suggest
a possible mechanistic role for MAPK in coronary micro-
vascular dysfunction. Considering the extensive involve-
ment of these signal transduction pathways in other organ
systems and in processes such as vascular permeability and
cytokine production, MAPK likely contribute to other as-
pects of the inflammatory response to CPB as well. Thus,
the MAPK signal transduction pathways provide potential
sites of intervention to prevent deleterious effects of cardio-
plegia and CPB.
Conclusions
MAPK are essential components of signal transduction
pathways implicated in several physiologic responses to
cardiac surgery. During cardiac surgery, the myocardium is
exposed to ischemia, vasoactive agents, and physical stress
such as shear force and stretch, all of which alter the activity
of MAPK pathways. The increased vascular permeability,
vasomotor dysfunction, and cytokine production associated
with the inflammatory response to CPB may be mediated in
part by MAPK. Significant organ dysfunction may result
from derangements in these physiologic processes, which
were suggested to involve MAPK pathways in cardiac,
pulmonary, renal, mesenteric, and central nervous systems.
Activation of the MAPK cascades during reperfusion also
may be associated with reperfusion injury as well as cardiac
arrhythmias. Finally, we have shown that changes in MAPK
activity in patients due to cardioplegia and CPB are in-
volved in coronary microcirculatory dysfunction, with po-
tential detrimental effects on myocardial perfusion. As the
mechanisms of MAPK pathways in cardiovascular physiol-
ogy are further uncovered, our potential to develop methods
to prevent morbidity associated with cardiac surgery with
cardioplegia and CPB may be greatly improved.
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